Literature DB >> 9988189

Recombinant human monoclonal antibodies to Ebola virus.

T Maruyama1, P W Parren, A Sanchez, I Rensink, L L Rodriguez, A S Khan, C J Peters, D R Burton.   

Abstract

Human Fab (IgG1kappa) phage display libraries were constructed from bone marrow RNA from 2 donors who recovered from infection with Ebola (EBO) virus during the 1995 outbreak in Kikwit, Democratic Republic of the Congo. The libraries were initially panned against a radiation-inactivated EBO virus-infected Vero cell lysate, but only weak binders were identified. In contrast, panning against secreted EBO glycoprotein (SGP) resulted in Fabs showing very strong reactivity with SGP in ELISA. These Fabs also reacted with a virion membrane preparation. The Fabs were strongly positive in IFAs with cells infected with EBO (subtype Zaire) virus but negative with uninfected cells, with a characteristic punctate staining pattern in the cytoplasm. The Fabs showed weak or no reactivity with the virus cell lysate although donor serum did react. The Fabs are now being characterized in structural and functional terms. Major interest will focus on the ability of antibodies to neutralize EBO virus and, later, to protect animals against infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988189     DOI: 10.1086/514280

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Recombinant monoclonal human antibodies against Ebola virus.

Authors:  N V Tikunova; A A Kolokol'tsov; A A Chepurnov
Journal:  Dokl Biochem Biophys       Date:  2001 May-Jun       Impact factor: 0.788

3.  Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.

Authors:  Graham Simmons; Rouven J Wool-Lewis; Frédéric Baribaud; Robert C Netter; Paul Bates
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 6.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

7.  Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus.

Authors:  Daniel Olal; Ana I Kuehne; Shridhar Bale; Peter Halfmann; Takao Hashiguchi; Marnie L Fusco; Jeffrey E Lee; Liam B King; Yoshihiro Kawaoka; John M Dye; Erica Ollmann Saphire
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

8.  Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.

Authors:  Jeffrey E Lee; Ana Kuehne; Dafna M Abelson; Marnie L Fusco; Mary Kate Hart; Erica Ollmann Saphire
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

9.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Authors:  John Misasi; Morgan S A Gilman; Masaru Kanekiyo; Miao Gui; Alberto Cagigi; Sabue Mulangu; Davide Corti; Julie E Ledgerwood; Antonio Lanzavecchia; James Cunningham; Jean Jacques Muyembe-Tamfun; Ulrich Baxa; Barney S Graham; Ye Xiang; Nancy J Sullivan; Jason S McLellan
Journal:  Science       Date:  2016-02-25       Impact factor: 47.728

10.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.